Presartan-50 is intended for use in the following diseases: arterial hypertension in adult patients, as well as in children whose age is over 6 years old; kidney disease in adult patients with type II diabetes mellitus with proteinuria and hypertension as part of blood pressure; chronic heart failure in patients over 60 years of age, when the use of ACE inhibitors (ACE) is contraindicated or impossible due to incompatibility, as well as when coughing; reducing the risks of mortality and cardiovascular complications in patients with hypertrophy and arterial hypertension of the left ventricle.
Presartan-50 Composition and release form
The drug is produced in the form of yellow biconvex oval film-coated tablets. The tablets are embossed with “50” on one side, and “BL” on the other. The active ingredients in the preparation are potassium losartan 50 mg and hydrochlorothiazide 12.5 mg, as well as additional components: corn starch, sodium starch, colloidal silicon dioxide, microcrystalline cellulose, quinoline yellow, talc, magnesium stearate, titanium dioxide, hypromellose, polyethylene glycol. A cardboard box contains 2 blisters of 14 tablets each.
Presartan-50 is a combined antihypertensive drug used to treat hypertension. Reception of this drug can significantly reduce the total number of fatalities in cardiovascular diseases, myocardial infarction and stroke in patients with left ventricular hypertrophy and arterial hypertension, it also protects the kidneys in patients with type II diabetes mellitus with proteinuria.
Presartan-50 is intended for use in the following diseases:
- arterial hypertension in adult patients, as well as in children whose age is over 6 years old;
- kidney disease in adult patients with type II diabetes mellitus with proteinuria and hypertension as part of blood pressure;
- chronic heart failure in patients over 60 years of age, when the use of ACE inhibitors (ACE) is contraindicated or impossible due to incompatibility, as well as when coughing;
- reducing the risks of mortality and cardiovascular complications in patients with hypertrophy and arterial hypertension of the left ventricle.
The drug is contraindicated for use in severe violations of the functionality of the kidneys and liver and hypersensitivity to substances that are part of the tablets.
Application during pregnancy and lactation
The drug is not advisable for women in the first trimester of pregnancy, and in the second and third trimester and during breastfeeding, the drug is contraindicated.
Method of administration and dosage
For adult patients, the dose at the beginning of treatment and the maintenance dose of the drug is 1 tablet once a day. The most positive effect after the start of treatment is achieved at 3-6 weeks of use. If necessary, after 2-4 weeks, the daily dose can be increased to 2 tablets. Presartan-50 can be used in combination with other antihypertensive drugs.
The drug must be taken with plenty of water and regardless of food intake.
In heart failure, the initial daily dose of Presartan-50 is 12.5 mg, after a week it can be increased to 25 mg, and after another up to 50 mg, depending on how the patient will tolerate the drug.
For children over 6 years old, weighing more than 20 kg and less than 50 kg, the daily dose is 25 mg. In some cases, it is possible to increase the dose to 50 mg 1 time per day.
If a child weighs more than 50 kg, the daily dose is usually 50 mg. In some cases, it is possible to increase the dose to 100 mg 1 time per day.
For patients over 75 years of age, treatment is started with a dose of 25 mg.
In case of an overdose of the drug, tachycardia, arterial hypotension and bradycardia are most likely. In case of intoxication, it is necessary to take activated charcoal, further treatment depends on the elapsed time after taking the drug and on the severity of the character and symptoms.
The use of the drug can cause many adverse reactions: dizziness, cough, vertigo, runny nose, pharyngitis and sinusitis, upper respiratory tract infections, weakness, asthenia, photosensitivity, hypoglycemia, anemia, erythroderma and hyperkalemia, thrombocytopenia, migraine, tinnitus, dysgeusia. Also, negative reactions include: drowsiness, headache, muscle cramps, palpitation, angina pectoris and tachycardia, hypotension, rash, constipation, paresthesia, nausea, urticaria, itching, myalgia, arthralgia, rhabdomyolysis, diarrhea, vomiting. Treatment with Presartan-50 can lead to changes in renal function, hypersensitivity reactions, edema, depression, dose-dependent orthostatic effect, stroke, shortness of breath, fainting, insomnia, abdominal pain and pancreatitis.
Storage conditions and periods
Presartan-50 must be stored at a temperature that does not exceed + 25 ° C, away from children, in its original packaging. The shelf life of this drug is 24 months from the date of issue.